Contact

 

R&D Programs

ACINETOCLINIC

ACINETOCLINIC is focused to complete the transition to human clinical phases (Phase I in healthy volunteers) of the first universal vaccine against drug resistant Acinetobacter baumannii (VXD-001). The main objective of the progamme funding of this project is promotion of technological development, innovation, and research of high quality.

The ACINETOCLINIC consortium is led by Vaxdyn and includes Laboratorio Reig Jofre, DraconisPharma, FISEVI and Centro Tecnológico Leitat.

ACINETOCLINIC is funded by RETOS-COLABORACIÓN 2016 Programme of the Spanish Ministry of Economy, Industry and Competitiveness co-financed with ERDF Programme. 

Logo VAXDYN Logo Reig Jofre H1Logo draconislogo leitat 2016Logo FISEVI

Logo MINECO paginas webIIlogo FEDER

 

BIOMAP

BIOMAP is focused on the design of assays to obtain bioactive molecules with the pharmaceutical criteria for quality, security and efficacy designs (Quality by design or QbD). To achieve this goal the consortium will use synergies between the different members of the consortium to develop molecules from the pipeline of the different members.

The QbD method will reduce time and cost to develop the different molecules included in the project.

The BIOMAP consortium is led by Laboratories Rovi and includes Bionaturis, Vivacell Biotechnology Spain, and Vaxdyn.

In this project, Vaxdyn received funding from the CDTI from the Feder-Interconecta Programme, with the support of the Spanish Ministry of Economy and Competitiveness.

ADELIS

The objective of ADELIS is to develop injectable pharmaceuticals that address medical necessities from different health sectors

The ADELIS consortium is led by Laboratories Rovi and includes Bionaturis, Biomedal, Athea and Vaxdyn.

In this project, Vaxdyn received funding from the CDTI from the Feder-Interconecta Programme, with the support of the Spanish Ministry of Economy and Competitiveness.

ACINETOVAX

The objective of ACINETOVAX is to reduce the incidence of multidrug resistant Acinetobacter baumannii infections developing a vaccine to prevent the infections caused by this pathogen.

ACINETOVAX was financed by INNPACTO 2011 Programme of the Spanish Ministry of Science and Innovation co-financed with ERDF Programme.

ACINETOCLINIC is focused to complete the transition to human clinical phases (Phase I in healthy volunteers) of the first universal vaccine against drug resistant Acinetobacter baumannii (VXD-001).